Shareholders of Oculis Holding AG (NASDAQ: OCS) lost nearly $7 per share, more than 23%, in a single trading session when the company disclosed that its Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet the primary endpoint -- mean change in best-corrected visual acuity at week 52 -- in diabetic macular edema. Oculis simultaneously announced it would not pursue an FDA filing for the DME indication. Investors who lost money on OCS are encouraged to submit their information now . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
The approximately 23.4% single-day decline followed disclosure that OCS-01 eye drops -- the company's lead pipeline candidate targeting what Oculis had described as a multi-billion-dollar market -- did not achieve statistical significance on the primary efficacy measure across both pivotal trials. The company stated it would redirect resources to other pipeline candidates and would not file a New Drug Application for the DME indication.
Prior to the disclosure, Oculis had described the DIAMOND program as positioned for topline results in 2026 with a subsequent NDA submission planned for Q4 2026. CEO Sherif had previously claimed it was a product they “know that it works … really the only risk … is execution.” Despite their claimed “obsessive execution,” the studies ultimately failed and the stock's 23% decline erased hundreds of millions of dollars in market capitalization in a single session.
Shareholders who purchased OCS and suffered a loss are encouraged to click here to discuss their legal rights . You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities investigations and recoveries. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the OCS Investigation
Q: Who is eligible to participate in the OCS investigation? A: Investors who purchased OCS stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: How much did OCS stock drop? A: Shares fell approximately 23% in a single trading session after the company disclosed that Phase 3 DIAMOND-1 and DIAMOND-2 trials for OCS-01 failed to meet the primary endpoint in diabetic macular edema and announced it would not pursue an FDA filing for that indication.
Q: What do OCS investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.
Q: What if I already sold my OCS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought OCS and sold at a loss may still participate in the investigation.
Q: What does it cost me to participate? A: Nothing. Securities investigations and any resulting actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: Do I need to go to court or give testimony? A: No. Participating in the investigation does not require court appearances or depositions. The overwhelming majority of affected investors never appear in court.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260603198583/en/
/Micron%20Technology%20Inc_%20logo%20on%20building-by%20vzphotos%20vis%20iStock.jpg)
/AI%20(artificial%20intelligence)/AI%20engineer%20working%20on%20laptop%20by%20ART%20STOCK%20CREATIVE%20via%20Shutterstock.jpg)
/A%20corporate%20office%20for%20IBM%20by%20HJBC%20via%20Adobe%20Stock.jpeg)